Alzamend rises after completing mid-stage brain lithium study

Alzamend Neuro

19/11/2025 13:34

** Shares of clinical-stage drug developer Alzamend Neuro ALZN.O rise 5.74% to $2.58 premarket

** Co says it finished the clinical portion of a mid-stage trial of AL001, a lithium-based therapy for Alzheimer's and mood disorders

** Study compared AL001 with marketed lithium carbonate to measure lithium levels in blood and brain using advanced imaging, co says

** Co says goal is to deliver lithium more effectively to the brain while reducing systemic side effects and avoiding frequent blood tests

** ALZN expects to release the main results in early 2026

** Up to last close, stock down ~77% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))